C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Ravulizumab (Primary)
- Indications Acute kidney injury; Thrombotic microangiopathy
- Focus Therapeutic Use
- 31 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2022 Planned End Date changed from 1 Nov 2021 to 1 Nov 2023.
- 25 Jul 2022 Planned primary completion date changed from 1 May 2021 to 1 May 2023.